The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.
Researchers are revealing the complexity of the microbial community living on the body—and paving the way for new bacteria-targeting treatments for acne and other dermatological conditions.
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.